Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD.
Citations
Citations to this article as recorded by
FIB‐4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD Ya‐Chin Huang, Chih‐Wen Wang, Jiun‐Chi Huang, Po‐Cheng Liang, Ming‐Lun Yeh, Yi‐Yu Chen, Yi‐Hung Lin, Tyng‐Yuan Jang, Yu‐Ju Wei, Ming‐Yen Hsieh, Chao‐Kuan Huang, Hsu‐Han Chien, Chia‐Jen Wu, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Chia‐I Lin, Chung‐Fen Journal of Gastroenterology and Hepatology.2026; 41(1): 332. CrossRef
Serum mir-181a as a potential serological biomarker for metabolic dysfunction-associated fatty liver disease: A cross sectional study Ke-Gong Xiong, Jin-Feng Kong, Tai-Shun Lin, Qing-Biao Lin, Kun-Yu Ke Medicine.2026; 105(4): e47290. CrossRef
A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B Moon Haeng Hur, Terry Cheuk-Fung Yip, Seung Up Kim, Hyun Woong Lee, Han Ah Lee, Hyung-Chul Lee, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Hwi Young Kim, Yeon Seok Seo, Hyunjae Shin, Jeayeon Park, Yunmi Ko, Yo Journal of Hepatology.2025; 82(2): 235. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure Kai-Chun Chang, Tung-Hung Su, Cho-Kai Wu, Shang-Chin Huang, Tai-Chung Tseng, Chun-Ming Hong, Shih-Jer Hsu, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao European Journal of Heart Failure.2025; 27(3): 512. CrossRef
Metabolic dysfunction-associated steatotic liver disease and its associated health risks Xia-Rong Liu, Szu-Ching Yin, Yi-Ting Chen, Mei-Hsuan Lee Journal of the Chinese Medical Association.2025; 88(5): 343. CrossRef
Fatty Liver and Hyperuricemia in Workers: Combined Effects on Metabolic Dysfunction and the Role of Lifestyle Factors Jui-Hua Huang, Ren-Hau Li, Hon-Ke Sia, Feng-Cheng Tang Metabolites.2025; 15(5): 318. CrossRef
Application of insulin resistance score in type 2 diabetes mellitus complicated with fatty liver and liver fibrosis Shaojie Duan, Mengdie Chen, Jie Chen, Yaojian Shao, Xiaolong Jin, Chaohui Wang, Ping Feng, Xiaosheng Teng, Zhenjun Yu European Journal of Gastroenterology & Hepatology.2025; 37(10): 1155. CrossRef
The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace Biomedicine & Pharmacotherapy.2025; 190: 118375. CrossRef
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer Pin-Nan Cheng, Ming-Lung Yu Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
MAFLD: from a disease framework to patient care Mohammed Eslam, Jacob George Hepatology International.2024; 18(S2): 823. CrossRef
Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus Wei-Fan Hsu American Journal of Cancer Research.2024; 14(4): 1914. CrossRef
The unfolded features on the synchronized fashion of gut microbiota and Drynaria rhizome against obesity via integrated pharmacology Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Dong Joon Kim, Ki-Tae Suk Food Chemistry.2024; 460: 140616. CrossRef
High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang Scientific Reports.2024;[Epub] CrossRef
MASLD: an emerging factor in the pathophysiology and clinical management of ICC Zong-Long Li, Jia-Lu Chen, Yue Tang, De-Long Qin, Zhao-Hui Tang Hepatoma Research.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Factors Influencing Overall Survival Period of Stage IV Cancer Patients Wen Pei Chang, Yen Kuang Lin, Shashank Kaushik European Journal of Cancer Care.2025;[Epub] CrossRef
First
Prev
